Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSTX Stock Price Chart Interactive Chart >
PSTX Price/Volume Stats
|Current price||$7.95||52-week high||$13.98|
|Prev. close||$7.67||52-week low||$7.53|
|Day high||$7.98||Avg. volume||266,986|
|50-day MA||$8.63||Dividend yield||N/A|
|200-day MA||$9.25||Market Cap||495.60M|
Poseida Therapeutics Inc. (PSTX) Company Bio
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Most Popular Stories View All
PSTX Latest News Stream
|Loading, please wait...|
PSTX Latest Social Stream
View Full PSTX Social Stream
Latest PSTX News From Around the Web
Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Eric Ostertag, Chief Executive Officer at Poseida Therapeutics (NASDAQ:PSTX), made a large buy and sell of company shares on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 14, Eric Ostertag bought 21,281 Poseida Therapeutics shares at prices ranging from $1.17 to $9.15 per share, for a total of $172,729. They then sold their shares on the same day in the open market at a price of $8.14 to rais
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:
Every investor in Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) should be aware of the most powerful shareholder groups...
The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX ) hard last August, but since
The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy. The Company announced interim results for P-PSMA-101, solid tumor autologous CAR-T product candidate for metastatic castrate-resistant prostate cancer (mCRPC). The Company was bullish on the presentation today, but investors apparently were not impressed. The caveat is that it is Phase
PSTX Price Returns